Abgenix Inc. s stock took a small hit Friday following the disclosure that a Phase IIa study of its rheumatoid arthritis candidate failed to meet its endpoints.

Abgenix Inc. s stock took a small hit Friday following the disclosure that a Phase IIa study of its rheumatoid arthritis candidate failed to meet its endpoints.

BioCryst Pharmaceuticals Inc. started out the flu season earlier this week by commencing Phase III enrollment in the United States for its flu treatment, peramivir, after getting clearance from the FDA to resume the study.

BioCryst Pharmaceuticals Inc. started out the flu season earlier this week by commencing Phase III enrollment in the United States for its flu treatment, peramivir, after getting clearance from the FDA to resume the study.

Analysts say the FDA s failure to accept ImClone Systems Inc. s rolling biologics license application for Erbitux in irinotecan-refractory colorectal cancer is expected to delay market launch by about six months.

Analysts say the FDA s failure to accept ImClone Systems Inc. s rolling biologics license application for Erbitux in irinotecan-refractory colorectal cancer is expected to delay market launch by about six months.